IL314797A - Combination therapies for cancer treatment that include B7-H4 drug antibody - Google Patents
Combination therapies for cancer treatment that include B7-H4 drug antibodyInfo
- Publication number
- IL314797A IL314797A IL314797A IL31479724A IL314797A IL 314797 A IL314797 A IL 314797A IL 314797 A IL314797 A IL 314797A IL 31479724 A IL31479724 A IL 31479724A IL 314797 A IL314797 A IL 314797A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- drug conjugate
- combination therapies
- antibody drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310967P | 2022-02-16 | 2022-02-16 | |
| US202263378295P | 2022-10-04 | 2022-10-04 | |
| PCT/EP2023/053720 WO2023156434A1 (en) | 2022-02-16 | 2023-02-15 | Combination therapies for treatment of cancer comprising b7-h4 antibody drug conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314797A true IL314797A (en) | 2024-10-01 |
Family
ID=85283493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314797A IL314797A (en) | 2022-02-16 | 2023-02-15 | Combination therapies for cancer treatment that include B7-H4 drug antibody |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230310636A1 (https=) |
| EP (1) | EP4479428A1 (https=) |
| JP (1) | JP2025508380A (https=) |
| KR (1) | KR20240150781A (https=) |
| AU (1) | AU2023221516A1 (https=) |
| CA (1) | CA3250868A1 (https=) |
| CL (1) | CL2024002434A1 (https=) |
| CO (1) | CO2024012148A2 (https=) |
| CR (1) | CR20240385A (https=) |
| IL (1) | IL314797A (https=) |
| MX (1) | MX2024009972A (https=) |
| TW (1) | TW202348252A (https=) |
| WO (1) | WO2023156434A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025103407A1 (zh) * | 2023-11-16 | 2025-05-22 | 江苏豪森药业集团有限公司 | 抗体药物偶联物和多腺苷二磷酸核糖聚合酶抑制剂的联合应用 |
| TW202539742A (zh) * | 2024-02-08 | 2025-10-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗體藥物偶聯物和抗ｖｅｇｆ抗體的聯合應用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| ZA200503075B (en) | 2002-11-07 | 2006-09-27 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| NZ584514A (en) | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| SG11201608192SA (en) | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| WO2015155345A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| WO2016040724A1 (en) * | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
| EP3612567B1 (en) * | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| MX2021011812A (es) | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| BR112023004415A2 (pt) | 2020-09-11 | 2023-05-09 | Medimmune Ltd | Moléculas terapêuticas de ligação a b7-h4 |
-
2023
- 2023-02-10 TW TW112104876A patent/TW202348252A/zh unknown
- 2023-02-15 WO PCT/EP2023/053720 patent/WO2023156434A1/en not_active Ceased
- 2023-02-15 CR CR20240385A patent/CR20240385A/es unknown
- 2023-02-15 CA CA3250868A patent/CA3250868A1/en active Pending
- 2023-02-15 JP JP2024547662A patent/JP2025508380A/ja active Pending
- 2023-02-15 MX MX2024009972A patent/MX2024009972A/es unknown
- 2023-02-15 IL IL314797A patent/IL314797A/en unknown
- 2023-02-15 AU AU2023221516A patent/AU2023221516A1/en active Pending
- 2023-02-15 US US18/169,497 patent/US20230310636A1/en active Pending
- 2023-02-15 KR KR1020247030173A patent/KR20240150781A/ko active Pending
- 2023-02-15 EP EP23705984.5A patent/EP4479428A1/en active Pending
-
2024
- 2024-08-14 CL CL2024002434A patent/CL2024002434A1/es unknown
- 2024-09-06 CO CONC2024/0012148A patent/CO2024012148A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025508380A (ja) | 2025-03-26 |
| KR20240150781A (ko) | 2024-10-16 |
| US20230310636A1 (en) | 2023-10-05 |
| MX2024009972A (es) | 2024-08-26 |
| CR20240385A (es) | 2024-10-16 |
| WO2023156434A1 (en) | 2023-08-24 |
| AU2023221516A1 (en) | 2024-09-19 |
| CA3250868A1 (en) | 2023-08-24 |
| TW202348252A (zh) | 2023-12-16 |
| CL2024002434A1 (es) | 2024-11-08 |
| CO2024012148A2 (es) | 2024-09-30 |
| EP4479428A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314797A (en) | Combination therapies for cancer treatment that include B7-H4 drug antibody | |
| IL325744A (en) | Combination therapies for cancer treatment | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| BR112019023909A2 (pt) | método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio. | |
| MX2016001541A (es) | Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos. | |
| CA3261336A1 (en) | METHODS OF TREATMENT FOR A DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY-DRUG CONJUGATIONS | |
| HK40120146A (en) | Combination therapies for treatment of cancer comprising b7-h4 antibody drug conjugate | |
| EP4157246B8 (en) | Therapeutic combination for the treatment of breast cancer | |
| EP4190340A4 (en) | Therapeutic drug or diagnostic drug for cancer | |
| EP4226945A4 (en) | MEDICINES FOR THE TREATMENT OF CANCER | |
| CA3275305A1 (en) | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies | |
| AU2023435819A1 (en) | Drug combination for treatment of pancreatic cancer | |
| IL320200A (en) | Antibodies for cancer treatment anti-BSSL | |
| CA3270474A1 (en) | Anti-bssl antibodies for the treatment of cancer | |
| CA3292276A1 (en) | Methods of treatment using anti-c-met antibody drug conjugates | |
| HK40128038A (en) | Combination therapies for treatment of cancer | |
| CA3263276A1 (en) | Polytherapy for the treatment of cancer | |
| CA3290371A1 (en) | B7-h4 therapeutic binding molecules for the treatment of cancer | |
| IL321145A (en) | Combination therapy for cancer treatment that includes anti-PD-L1 and anti-CD73 antibodies | |
| AU2024351114A1 (en) | Dosage of antibody drug conjugate rinatabart sesutecan | |
| CA3300229A1 (en) | Dosage of antibody drug conjugate rinatabart sesutecan | |
| CA3233757A1 (en) | Approved drug products for the treatment of metastatic castration-resistant prostate cancer | |
| HK40103804A (en) | Anti-survivin antibodies for treatment of autoimmune diseases | |
| EP4525994A4 (en) | Combination therapies for treatment of cancer | |
| CA3299976A1 (en) | Use of anti-interleukin-11 antibody in preparation of drug for treating tumors |